Susquehanna International Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.47M | Buy |
59,200
+35,300
| +148% | +$841K | ﹤0.01% | 6948 |
|
|
2025
Q4 | $558K | Sell |
23,900
-82,600
| -78% | -$1.84M | ﹤0.01% | 8515 |
|
|
2025
Q3 | $2.1M | Buy |
+106,500
| New | +$2.19M | ﹤0.01% | 5685 |
|
|
2024
Q4 | – | Sell |
-11,400
| Closed | -$227K | – | 12323 |
|
|
2024
Q3 | $227K | Sell |
11,400
-9,400
| -45% | -$174K | ﹤0.01% | 10203 |
|
|
2024
Q2 | $322K | Buy |
20,800
+9,300
| +81% | +$145K | ﹤0.01% | 9290 |
|
|
2024
Q1 | $183K | Buy |
+11,500
| New | +$173K | ﹤0.01% | 10696 |
|
|
2023
Q4 | – | Sell |
-12,600
| Closed | -$147K | – | 12460 |
|
|
2023
Q3 | $147K | Sell |
12,600
-36,200
| -74% | -$484K | ﹤0.01% | 10559 |
|
|
2023
Q2 | $656K | Sell |
48,800
-174,900
| -78% | -$2.52M | ﹤0.01% | 7679 |
|
|
2023
Q1 | $3.71M | Buy |
223,700
+24,700
| +12% | +$407K | ﹤0.01% | 3909 |
|
|
2022
Q4 | $3.7M | Buy |
199,000
+180,000
| +947% | +$2.77M | ﹤0.01% | 3689 |
|
|
2022
Q3 | $244K | Buy |
+19,000
| New | +$225K | ﹤0.01% | 10326 |
|
|
2021
Q4 | – | Sell |
-12,500
| Closed | -$66K | – | 13185 |
|
|
2021
Q3 | $66K | Sell |
12,500
-27,800
| -69% | -$152K | ﹤0.01% | 12248 |
|
|
2021
Q2 | $232K | Buy |
40,300
+20,100
| +100% | +$104K | ﹤0.01% | 11276 |
|
|
2021
Q1 | $93K | Sell |
20,200
-4,200
| -17% | -$16.7K | ﹤0.01% | 11889 |
|
|
2020
Q4 | $81K | Sell |
24,400
-89,800
| -79% | -$302K | ﹤0.01% | 10590 |
|
|
2020
Q3 | $339K | Buy |
114,200
+13,100
| +13% | +$51.2K | ﹤0.01% | 8462 |
|
|
2020
Q2 | $467K | Buy |
101,100
+11,300
| +13% | +$50.8K | ﹤0.01% | 7506 |
|
|
2020
Q1 | $346K | Buy |
+89,800
| New | +$369K | ﹤0.01% | 7702 |
|
|
2019
Q4 | – | Sell |
-22,600
| Closed | -$120K | – | 9812 |
|
|
2019
Q3 | $120K | Sell |
22,600
-137,200
| -86% | -$731K | ﹤0.01% | 9460 |
|
|
2019
Q2 | $614K | Buy |
159,800
+58,800
| +58% | +$254K | ﹤0.01% | 6832 |
|
|
2019
Q1 | $515K | Buy |
+101,000
| New | +$297K | ﹤0.01% | 6214 |
|
|
2018
Q4 | – | Sell |
-209,300
| Closed | -$791K | – | 9042 |
|
|
2018
Q3 | $791K | Buy |
209,300
+151,900
| +265% | +$476K | ﹤0.01% | 5688 |
|
|
2018
Q2 | $179K | Buy |
57,400
+32,300
| +129% | +$98K | ﹤0.01% | 8711 |
|
|
2018
Q1 | $60K | Buy |
25,100
+12,500
| +99% | +$41.5K | ﹤0.01% | 8902 |
|
|
2017
Q4 | $49K | Sell |
12,600
-9,900
| -44% | -$32.7K | ﹤0.01% | 8909 |
|
|
2017
Q3 | $57K | Sell |
22,500
-112,500
| -83% | -$309K | ﹤0.01% | 8511 |
|
|
2017
Q2 | $373K | Buy |
+135,000
| New | +$282K | ﹤0.01% | 7178 |
|
|
2015
Q3 | – | Sell |
-52,500
| Closed | -$217K | – | 9665 |
|
|
2015
Q2 | $217K | Buy |
+52,500
| New | +$209K | ﹤0.01% | 9150 |
|
|
2014
Q4 | – | Sell |
-22,900
| Closed | -$76K | – | 9651 |
|
|
2014
Q3 | $76K | Sell |
22,900
-6,200
| -21% | -$16.2K | ﹤0.01% | 9138 |
|
|
2014
Q2 | $74K | Buy |
+29,100
| New | +$62.2K | ﹤0.01% | 9519 |
|
Other funds holding CPRX
VCM
DM
VPM
Susquehanna International Group's CPRX Position: Q1 2026 in Review
Susquehanna International Group increased its Catalyst Pharmaceutical (CPRX) stake by 419% in Q1 2026, buying an estimated $16.4M and bringing the position to 852,820 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2158.
Susquehanna International Group first reported a position in CPRX in Q2 2014 and has held it in 42 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Susquehanna International Group held 852,820 shares of Catalyst Pharmaceutical worth $21.1M as of Q1 2026.
- Susquehanna International Group bought 688,608 Catalyst Pharmaceutical shares in Q1 2026, an estimated $16.4M.
- Catalyst Pharmaceutical made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2158 holding.
- Susquehanna International Group first reported a position in Catalyst Pharmaceutical in Q2 2014 and has held it in 42 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.